medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2013, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2013; 29 (2)

Clonal evolution in chronic myeloid leukemia

Lavaut SK, Pavón MV

Language: Spanish
References: 16
Page:
PDF size: 48.58 Kb.


ABSTRACT

Clonal evolution in chronic myeloid leukemia is defined as the presence of a variety of additional, nonrandom chromosomal abnormalities besides the Philadelfia chromosome. It occurs in approximately 30 % of patients in accelerated phase and 80 % of patients in blastic phase. It is considered a criterion for accelerated phase. Although it is associated with a poor prognosis, its significance is controversial. It depends on the specific cytogenetic abnormality, its frequency in karyotype study, the association with other progression clinical and cytogenetic alterations, its relationship with the time of appearance during the course of the disease and the therapy used.


REFERENCES

  1. GoldmanJ, Melo J. Chronic myeloid leukemia. Advances in biology and new approchaes to treatment. N Engl J Med. 2003 Oct; 349(15):1451-64.

  2. Hehlmann R, Berger U, Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol. 2005 Aug; 84(8):487-97.

  3. Vargas P. Evolución citogenética y molecular en pacientes tratados con Imatinib. Gac Med Mex. 2003 Mar- Abril; 139(2):124-7.

  4. Majlis A, Smith TL, Talpaz M, O Brien S, Rios MB, Kantarjian HM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol. 1996 Jan; 14(1): 196-203.

  5. Cortés J, Kantarjian H. Advanced phase chronic myeloid leukemia. Sem Hematol. 2003 Jan; 40(1):79-86.

  6. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer .2010 Jun; 116(11): 2673-81.

  7. Cortes J, O Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):671-84.

  8. Pavon V, Hernández P, Martínez G, Agramonte O, Jaime JC, Bravo Y. Leucemia mieloide crónica. Actualización en Citogenética y Biología Molecular. Rev Cubana Hematol Inmunol Hemoter 2005; 21(2). Disponible en:http://bvs.sld.cu/revistas/hih/vol21_2_05/hih03205.htm

  9. Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C, et al.Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011 Dec; 118(26): 6760-8.

  10. Holzerová M, Faber E, Veselovská J, Urbánková H, Balcárková J, Rozmanová S, et al. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: singlecenter results. Cancer Genet Cytogenet. 2009 May; 191(1): 1-9.

  11. Ahn JS, Kim YK, Lee SR, Yu L, Yang DH, Cho SH, et al. Coexisting with clonal evolution and BCR- ABL mutant in CML patients treated with second generation tyrosine kinase inhibitors. Cancer Res Treat. 2010 Mar; 42(1): 37-41.

  12. Sessions J. Chronic myeloid leukemia in 2007. Am J Health Syst Pharm. 2007 Dec 15; 64(24): 4-9.

  13. Cortes J, Talpaz M, Giles F, O Brien S, Rios MB, Shan J, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May; 101(10): 3794-800.

  14. O Dwyer ME, Mauro MJ, Kurilik G, Mori M, Ballesein S, Olson S, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002 Sep; 100(5): 1628-33.

  15. Falchi L, Rege-Cambrin G, Fava C, Donti E, Luzi D, Giuglano E, et al. Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution. Cancer Genet Cytogenet. 2010 Jun; 199(2): 139-42.

  16. Schnittger S, Bacher U, Dicker F, Kern W, Alpermann T, Haferlach T, et al. Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. Genes Chromosomes Cancer 2010 Oct; 49(10): 910- 8. http://www.ncbi.nlm.nih.gov/pubmed?term=16 - %09Schnittger%20S%2C%20Bacher%20U%2C%20Dicker%20F%2C%20Kern%20W %2C%20Alpermann%20T%2C%20Haferlach%20T%2C%20et%20al.%20Associations %20between%20imatinib%20resistance%20conferring%20mutations%20and%20Phila delphia%20positive%20clo nal%20cytogenetic%20evolution%20in%20CML.%20Genes%20Chromosomes%20Can cer%20%202010%3B%2049%2810%29%3A%20910 -8




2020     |     www.medigraphic.com